Jove
Visualize
Contact Us

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethionamide versus ethambutol-containing first-line regimens for TB meningitis.

Antimicrobial agents and chemotherapy·2026
Same author

The Double Burden: Understanding the Impact of Malnutrition on Childhood Cancer Outcomes in Resource-Limited Settings.

International journal of pediatrics·2026
Same author

Diabetes mellitus and its association with tuberculosis clinical presentation and treatment outcomes: results from a prospective cohort study in Ghana.

Frontiers in public health·2026
Same author

Population pharmacokinetics and safety of continuous oxacillin in preterm and term neonates and infants.

Antimicrobial agents and chemotherapy·2026
Same author

Exposure to the Four First-Line Anti-Tuberculosis Drugs and Treatment Outcomes: A Target Trial Emulation Study in Ghana.

Research square·2026
Same author

Pharmacokinetics of Dolutegravir in Children With HIV With and Without Tuberculosis Coinfection Treated According to World Health Organization Dosing Guidelines.

Journal of acquired immune deficiency syndromes (1999)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 24, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Antituberculosis therapy for 2012 and beyond.

Michael Lauzardo1, Charles A Peloquin

  • 1University of Florida, College of Medicine, 1600 SW Archer Road, PO Box 100486, Gainesville, FL 32610-0486, USA.

Expert Opinion on Pharmacotherapy
|February 16, 2012
PubMed
Summary
This summary is machine-generated.

Tuberculosis (TB) remains a global health crisis due to limited treatment options and drug resistance. New combination therapies, including novel drugs, show promise for shortening treatment and combating resistant strains.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Experiment Videos

Last Updated: May 24, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Area of Science:

  • Infectious Diseases
  • Global Health
  • Pharmacology

Background:

  • Tuberculosis (TB) is a historically significant infectious disease causing immense global suffering.
  • Current TB therapies are outdated (over 40 years old) and threatened by HIV and drug-resistant strains.
  • There is an urgent need for novel drugs and treatment strategies to combat TB.

Purpose of the Study:

  • To review current tuberculosis therapy.
  • To present new drug doses and combinations.
  • To discuss novel candidate drugs and therapeutic approaches.

Main Methods:

  • Review of existing tuberculosis treatment regimens.
  • Presentation of new drug combinations and dosages.
  • Discussion of emerging drug candidates and their potential impact.

Main Results:

  • New combination regimens, including PA 824 and TMC207 with existing drugs, are highly promising.
  • These novel combinations can shorten treatment for susceptible TB.
  • They offer potential utility against drug-resistant tuberculosis strains.

Conclusions:

  • Continued delivery of existing therapies is crucial.
  • Directly observed therapy and basic care are essential for maximizing new drug impact.
  • New drugs and combinations offer hope for saving lives and potentially eliminating TB.